Embla Medical hfOSSFF 92 EV-to-EBIT is 16.73 as of Jul. 07, 2026, which is 39% below its 10-year median of 27.37. GuruFocus rates OSSFF with a GF Score™ of 92/100 and a GF Value™ of $5.33. The stock has 2 warning signs investors should review. Among 466 Medical Devices & Instruments companies, Embla Medical hf ranks better than 56.01% on this metric.
Embla Medical hf (OTCPK:OSSFF) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Embla Medical hf's Enterprise Value for the quarter that ended in Mar. 2026 was $2,236.7 Mil.
Embla Medical hf's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $132.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Embla Medical hf EV-to-EBIT Related Terms
Embla Medical hf EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Embla Medical hf's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Embla Medical hf's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Embla Medical hf EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Embla Medical hf's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Embla Medical hf's EV-to-EBIT falls into.
Embla Medical hf's current Enterprise Value is $2,208.2 Mil.
Embla Medical hf's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $132.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Embla Medical hf (OSSFF) has a EV-to-EBIT of 16.73 as of Jul. 07, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Embla Medical hf and its competitors. This is 39% below median its historical median of 27.37. Over the past decade, Embla Medical hf's EV-to-EBIT has ranged from 16.42 to 162.98. According to the industry distribution chart, Embla Medical hf ranks #205 out of 466 companies in the Medical Devices & Instruments industry, placing it in the top 44%.
Is Embla Medical hf's EV-to-EBIT too high?
Embla Medical hf's current EV-to-EBIT of 16.73 is 39% below median its 10-year median of 27.37. Over the past 10 years, this metric has ranged from a low of 16.42 to a high of 162.98. The Medical Devices & Instruments industry median EV-to-EBIT is 18.64. Embla Medical hf's value of 16.73 is 10.2% below this industry median. Based on the distribution chart, Embla Medical hf ranks #205 out of 466 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Embla Medical hf has a GF Score™ of 92/100, reflecting its overall financial health beyond just this single metric.
How does Embla Medical hf's EV-to-EBIT compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Embla Medical hf ranks #205 out of 466 companies for EV-to-EBIT. This puts Embla Medical hf in the upper half of its industry. The industry median EV-to-EBIT is 18.64. Embla Medical hf's value of 16.73 is 10.2% below this benchmark. Historically, Embla Medical hf's own EV-to-EBIT has ranged from 16.42 to 162.98 over the past decade. While the company's 10-year median is 27.37 vs. the industry median of 18.64, Embla Medical hf has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 18.64, based on 466 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Embla Medical hf's current EV-to-EBIT of 16.73 is 10.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Embla Medical hf and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 18.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Embla Medical hf's current EV-to-EBIT is 16.73, which is 39% below median its own 10-year median of 27.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Embla Medical hf stock overvalued right now?
Embla Medical hf (OSSFF) has a current EV-to-EBIT of 16.73. The stock's GF Value™ is $5.33, compared to a current price of $4.15 — trading 22.1% below its estimated fair value. The current EV-to-EBIT is 16.73, which is 39% below median its 10-year median of 27.37 and 10.2% below the Medical Devices & Instruments industry median of 18.64. Embla Medical hf's overall GF Score™ is 92/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Embla Medical hf (OSSFF), the current EV-to-EBIT is 16.73 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Embla Medical hf (OSSFF) Overvalued in 2026?
Based on GuruFocus' analysis, Embla Medical hf stock appears to be undervalued.
The current stock price of $4.15 is trading 22.1% below its estimated GF Value™ of $5.33.
Key valuation signals for OSSFF:
EV-to-EBIT: 16.73 (39% below median its 10-year median of 27.37)
GF Value™: $5.33 vs. price of $4.15 (22.1% below fair value)
Industry Position: 10.2% below the Medical Devices & Instruments median (#205 of 466)
No single metric tells the full story. See the OSSFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Embla Medical hf operates as an orthopedic products company specializing in the design, development, manufacturing and sales of prosthetics and bracing & supports products. The company also provides patient care through a network of Orthotic and Prosthetic (O&P) facilities. It sells its products in multiple countries, with Europe and North America representing its principal markets. The company operates within three business segments: Prosthetics & Neuro Orthotics, Bracing & Supports and Patient Care. The majority of the company's revenue is derived from the Prosthetics & Neuro Orthotics, which includes products designed for users with varying mobility needs, ranging from lower-activity applications to solutions intended for more active use.
92GF Score
Get the complete analysis for OSSFF
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSSFF has been successfully added to your 
